Skip to content

Study · Non-randomized trial · n = 24 · 2007

5 results

Pharmacokinetics of an oral drug (acetaminophen) administered at various times relative to subcutaneous injection of pramlintide in subjects with type 2 diabetes.

Kellmeyer TA, Kesty NC, Wang Y, Frias JP, Fineman MS

Journal of clinical pharmacology26 Apr 2007Cited by 13 (Europe PMC)

PMID17463219 (opens in a new tab)DOI10.1177/0091270007300949 (opens in a new tab)PepBankPUB-17463219
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    In patients with type 2 diabetes, acetaminophen peak concentrations decreased 14% to 29% at 0, +1, or +2 hours relative to pramlintide versus placebo.

    In plain wordsIn patients with type 2 diabetes, acetaminophen peak levels were lower at the tested times after or with pramlintide than with placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseAcetaminophen maximum plasma concentration
    Study

    n = 24

    Comparator
    Acetaminophen given at 0 hours relative to placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    120 microg · subcutaneousAs given in this study (human).

    Measurements

    Acetaminophen peak concentration reduction
    14 to 29%
    acetaminophen at 0, +1, or +2 hours relative to pramlintide

    Source sentences

    Summary
    When acetaminophen administration occurred 0, +1, or +2 hours relative to pramlintide, the maximum observed plasma concentration of acetaminophen decreased 14% to 29%, and time to maximum observed plasma concentration increased by 0.8 to 1.2 hours compared with administration 0 hours relative to placebo.
    1 context sentence
    Summary · context
    Because gastric emptying affects oral medication absorption, this placebo-controlled, single-blind, crossover study examined the absorption of 1000 mg of acetaminophen elixir administered -2, -1, 0, +1, and +2 hours relative to pramlintide (120 microg) or 0 hours relative to placebo in 24 patients with type 2 diabetes.
  2. 02HumanNon-randomized trialPharmacokinetics

    In patients with type 2 diabetes, acetaminophen peak times increased 0.8 to 1.2 hours at 0, +1, or +2 hours relative to pramlintide versus placebo.

    In plain wordsIn patients with type 2 diabetes, acetaminophen peaked later at the tested times after or with pramlintide than with placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    IncreaseAcetaminophen time to maximum plasma concentration
    Study

    n = 24

    Comparator
    Acetaminophen given at 0 hours relative to placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    120 microg · subcutaneousAs given in this study (human).

    Measurements

    Acetaminophen peak time increase
    0.8 to 1.2 hours
    acetaminophen at 0, +1, or +2 hours relative to pramlintide

    Source sentences

    Summary
    When acetaminophen administration occurred 0, +1, or +2 hours relative to pramlintide, the maximum observed plasma concentration of acetaminophen decreased 14% to 29%, and time to maximum observed plasma concentration increased by 0.8 to 1.2 hours compared with administration 0 hours relative to placebo.
    1 context sentence
    Summary · context
    Because gastric emptying affects oral medication absorption, this placebo-controlled, single-blind, crossover study examined the absorption of 1000 mg of acetaminophen elixir administered -2, -1, 0, +1, and +2 hours relative to pramlintide (120 microg) or 0 hours relative to placebo in 24 patients with type 2 diabetes.
  3. 03HumanNon-randomized trialPharmacokinetics

    In patients with type 2 diabetes, pramlintide did not alter acetaminophen absorption extent measured by concentration-time area.

    In plain wordsIn patients with type 2 diabetes, pramlintide did not change the total amount of acetaminophen absorbed compared with placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changeAcetaminophen absorption extent
    Study

    n = 24

    Comparator
    Acetaminophen given at 0 hours relative to placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    120 microg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Pramlintide treatment slowed but did not alter the extent of acetaminophen absorption (area under the concentration-time curve).
    1 context sentence
    Summary · context
    Because gastric emptying affects oral medication absorption, this placebo-controlled, single-blind, crossover study examined the absorption of 1000 mg of acetaminophen elixir administered -2, -1, 0, +1, and +2 hours relative to pramlintide (120 microg) or 0 hours relative to placebo in 24 patients with type 2 diabetes.
  4. 04HumanNon-randomized trialSafety outcome

    In the crossover study in type 2 diabetes, no serious adverse events were reported.

    In plain wordsIn patients with type 2 diabetes, the study that tested pramlintide reported no serious adverse events.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableSerious adverse events
    Study

    n = 24

    Outcome group
    Adverse events · Whole body
    Studied dose
    120 microg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    No serious adverse events or withdrawals were reported.
    1 context sentence
    Summary · context
    Because gastric emptying affects oral medication absorption, this placebo-controlled, single-blind, crossover study examined the absorption of 1000 mg of acetaminophen elixir administered -2, -1, 0, +1, and +2 hours relative to pramlintide (120 microg) or 0 hours relative to placebo in 24 patients with type 2 diabetes.
  5. 05HumanNon-randomized trialSafety outcome

    In the crossover study in type 2 diabetes, no withdrawals were reported.

    In plain wordsIn patients with type 2 diabetes, the study that tested pramlintide reported no withdrawals.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableWithdrawals
    Study

    n = 24

    Outcome group
    Adverse events · Whole body
    Studied dose
    120 microg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    No serious adverse events or withdrawals were reported.
    1 context sentence
    Summary · context
    Because gastric emptying affects oral medication absorption, this placebo-controlled, single-blind, crossover study examined the absorption of 1000 mg of acetaminophen elixir administered -2, -1, 0, +1, and +2 hours relative to pramlintide (120 microg) or 0 hours relative to placebo in 24 patients with type 2 diabetes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.